Interim Kennedy Replacement: Incongrous Pick?

Fight disinformation: Sign up for the free Mother Jones Daily newsletter and follow the news that matters.


Over at the Sunlight Foundation, Paul Blumenthal runs down the resume of Paul Kirk, the ex-DNC chair and close Kennedy family friend who has been named to temporarily fill the late senator’s seat. Given Kirk’s background as a drug company lobbyist and ties to a top financial and insurance firm, Blumenthal notes, he seems like a slightly incongruous pick—even on an interim basis—with health care and financial reform topping the congressional agenda.

Some of Kirk’s recent career highlights:

Kirk is the CEO and Chairman of Kirk & Associates, a business consulting company, and sits on the board of both an insurance company, The Hartford Financial Group, and a timber and real estate company, Rayonier, Inc. Kirk also previously worked as a lobbyist for a pharmaceutical company, Aventis.

Kirk sits on the Compensation and Personnel Committee for The Hartford in charge of employee compensation and executive bonuses. While compensation fell significantly from 2007 to 2008, this did not keep The Hartford from escaping criticism for compensation policies. Ramani Ayer, CEO and Chairman of The Hartford, was named by Forbes Magazine one of the most overpaid executives in 2008…

In 1999, Kirk represented the pharmaceutical company Aventis as a lobbyist for Sullivan & Worcester. Kirk listed on his lobbying disclosure forms “FDA reform” as the sole issue and the Senate as the only body he was lobbying. In 1997, Congress passed and the President signed into law the FDA Modernization Act. One provision of the bill sought to curb red-tape and regulation to streamline the drug approval process. After the bill’s passage pharmaceutical companies and their lobbying arm, PhRMA, complained about the FDA’s speed at implementing the legislation and continued existence of some regulatory barriers. In 1999, the Senate held hearings on the subject with PhRMA President Alan Holmer told the Senate Health, Education, Pensions and Labor Committee that the legislation “fails to provide the regulatory relief Congress intended and actually codifies some of the agency’s prior-approval practices that Congress wanted to eliminate.” Kirk’s focus on “FDA reform” for Aventis was likely related to the complaints about the FDA Modernization Act and its implementation.

UPDATE: Here’s Public Citiizen’s Craig Holman commenting to the Boston Herald on Kirk’s appointment: “Obviously, this is a conflict of interest and raises serious concerns. It is distressing. There were many qualified people.”

Follow Daniel Schulman on Twitter.
 

We've never been very good at being conservative.

And usually, that serves us well in doing the ambitious, hard-hitting journalism that you turn to Mother Jones for. But it also means we can't afford to come up short when it comes to scratching together the funds it takes to keep our team firing on all cylinders, and the truth is, we finished our budgeting cycle on June 30 about $100,000 short of our online goal.

This is no time to come up short. It's time to fight like hell, as our namesake would tell us to do, for a democracy where minority rule cannot impose an extreme agenda, where facts matter, and where accountability has a chance at the polls and in the press. If you value our reporting and you can right now, please help us dig out of the $100,000 hole we're starting our new budgeting cycle in with an always-needed and always-appreciated donation today.

payment methods

We've never been very good at being conservative.

And usually, that serves us well in doing the ambitious, hard-hitting journalism that you turn to Mother Jones for. But it also means we can't afford to come up short when it comes to scratching together the funds it takes to keep our team firing on all cylinders, and the truth is, we finished our budgeting cycle on June 30 about $100,000 short of our online goal.

This is no time to come up short. It's time to fight like hell, as our namesake would tell us to do, for a democracy where minority rule cannot impose an extreme agenda, where facts matter, and where accountability has a chance at the polls and in the press. If you value our reporting and you can right now, please help us dig out of the $100,000 hole we're starting our new budgeting cycle in with an always-needed and always-appreciated donation today.

payment methods

We Recommend

Latest

Sign up for our free newsletter

Subscribe to the Mother Jones Daily to have our top stories delivered directly to your inbox.

Get our award-winning magazine

Save big on a full year of investigations, ideas, and insights.

Subscribe

Support our journalism

Help Mother Jones' reporters dig deep with a tax-deductible donation.

Donate